Tuesday, October 13, 2026
ExploreSearch
Via News
MarketFX

USD/CNH Bearish By 1% In The Last 10 Sessions

ViaNews Editorial Team

February 25, 2024

USD/CNH Bearish By 1% In The Last 10 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.73% for the last 10 sessions. At 13:08 EST on Sunday, 25 February, USD/CNH (USDCNH) is $7.20.

USD/CNH's yearly highs and lows, it's 0.004% up from its 52-week low and 0% down from its 52-week high.

News about

  • Eur/usd to be around 1.1000 at the end of 2024 and around 1.0800 at the end of 2025 – commerzbank. According to FXStreet on Friday, 23 February, "We now expect the EUR/USD exchange rate to be around 1.1000 at the end of 2024 (previously: 1.1200) and around 1.0800 at the end of 2025 (previously: 1.1000)."
  • Eur/usd weekly forecast: speculators should prepare for volatility this week - 25 February 2024. According to DailyForex on Sunday, 25 February, "The EUR/USD went into the weekend near the 1.08175 ratio, which may be viewed as an accomplishment by bullish traders who have been watching the 1.08000 level as a key psychological mark. ", "S economy shows less growth and weaker inflation, the EUR/USD would see a bullish rush."
  • Eur/usd is marginally up amid mixed German economic data. According to FXStreet on Friday, 23 February, "The EUR/USD is neutral to bearish bias, as the upward move toward the 50-day moving average (DMA) at 1.0885 was quickly rejected, with bears remaining in charge. "

More news about USD/CNH (USDCNH).

Categories

MarketFX

Tags

ForexForeign Exchange MarketCurrenciesUSDCNHUSD/CNHPrice DownFOREX Price DownForex Now
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,372 source documents archived
Query this data → isubstrate.com